STOCKHOLM, Sweden--(BUSINESS WIRE)--Meda AB (STO:MEDAA):
Integration of 3M’s pharma division in Europe went faster than forecasted.
All non-recurring restructuring costs recognised in Q1 2007.
Significantly improved underlying operating profit.
The Group’s net sales reached SEK 1,788.1 million (1,316.2).
Operating profit, excluding non-recurring items, increased to SEK 434.1 million (1) (225.6)(2).
